Skip to content
  • Home
  • Login
  • Register
The Journal of Commercial Biotechnology Logo
  • Home
  • Current
  • Archive
  • Ethical Guidelines
    • Author Guidelines
    • Submission Checklist
    • PMC Deposit Process/Matrix
    • Privacy Statement
  • About
    • About the Journal
    • Editorial Team
    • Indexing
    • Publication Fee
    • Open Access
  • Contact Us

JCB, Volume 18, Number 3, 2012

Editorial
Vol.18 No. 3 (2012)

Could personalized medicine be the driver for widespread price controls?

Yali Friedman

Everyone should agree that the benefits of personalized medicine — prescription of drugs most likely to benefit and least likely to harm individual or groups of patients — are

  • Abstract
  • Download PDF
Commentary
Vol.18 No. 3 (2012)

Innovating in the New Austerity

G. Steven Burrill

We are in the midst of dramatic changes in the way life sciences companies are funded. The model of funding a company with venture capital leading to an IPO is now the exception rather th

  • Abstract
  • Download PDF
Article
Vol.18 No. 3 (2012)

Innovative biotechnology industry strategies in the U.S.’ rapidly evolving payer environment

Sarah Stanton Collins

In 2010 healthcare represented 17.9% of GDP; its cost is growing significantly faster (~5%) than economic growth (~ 2%).  This growth presents a challenge to all payers, whether they a

  • Abstract
  • Download PDF
Article
Vol.18 No. 3 (2012)

Biotechnology in Argentina: Development and Resources

Claudia Zylberberg

Biotechnology related developments in Argentina have gained momentum in the past few years. The creation of the Ministry of Science, Technology and Innovative Production in 2007 that focu

  • Abstract
  • Download PDF
From the Classroom
Vol.18 No. 3 (2012)

A general model for training the next generation of Biotechnology entrepreneurs based on recent experience of USA-UK-South Africa collaborations

Karl J. Kunert

Preparing students for future entrepreneurial activity in the biotechnology industry is an important issue in many parts of the world because most countries seek to reap the benefits of i

  • Abstract
  • Download PDF
Case Study
Vol.18 No. 3 (2012)

Creating systemic oral transmucosal drug delivery strategies: Case study of APL-130277

Anthony Giovinazzo

This article addresses the strategic application of systemic oral transmucosal* (i.e., sublingual and buccal) drug delivery. Circumvention of first-pass hepatic metabolism in the gut, rap

  • Abstract
  • Download PDF
Case Study
Vol.18 No. 3 (2012)

What do hospital labs really need to streamline diagnostic testing: Apple vs. Microsoft environment?

Doug Millar

Molecular diagnostic (MDx) tests are now commonplace in virtually every hospital and pathology laboratory, however many questions have arisen, such as “What do diagnostic laboratori

  • Abstract
  • Download PDF
From the Boardroom
Vol.18 No. 3 (2012)

Biomarketing strategy and tactics 101 PART II of III

Dimitris Dogramatzis

The American Marketing Association defines marketing as the activity, set of institutions, and processes for creating, communicating, delivering, and exchanging offerings that have value for

  • Abstract
  • Download PDF
From the Boardroom
Vol.18 No. 3 (2012)

Disaster Planning for Biotechnology Companies

Frank Goudsmit

An earthquake in Japan cuts off the supply of key equipment and/or pharmaceutical ingredients to a biotechnology company with facilities in the U.S.  High winds and flooding from a

  • Abstract
  • Download PDF
Legal and Regulatory Updates
Vol.18 No. 3 (2012)

Are laboratory notebooks necessary in a first inventor to file world?

Deborah L. Lu

The importance of laboratory notebooks was long touted in the US to prove a date of invention. With the dawning of a first-to-file era in the US, the importance of laboratory notebooks has b

  • Abstract
  • Download PDF
Legal and Regulatory Updates
Vol.18 No. 3 (2012)

Mayo “nays”: The Supreme Court says no to patenting laws of nature

Jennifer A. Camacho

On March 20, 2012, the U.S. Supreme Court handed down its decision in Mayo Collaborative Services, et al v. Prometheus Laboratories, Inc (“Mayo”)

  • Abstract
  • Download PDF
Legal and Regulatory Updates
Vol.18 No. 3 (2012)

EU Legal & Regulatory Update

Ewan Grist

  • Abstract
  • Download PDF
Conference Report
Vol.18 No. 3 (2012)

Drug discovery & Development Landscape: New Trends in Academia-Industry Partnerships

Vasu Pestonjamasp

  • Abstract
  • Download PDF

Copyright © 2021 thinkBiotech Limited UK
Journal of Commercial Biotechnology
All rights reserved.
ISSN: 1462-8732 | eISSN: 1478-565X

Privacy Policy

thinkBiotech Limited
Journal of Commercial Biotechnology
63-66 Hatton Garden, London EC1N 8LE,
United Kingdom

GoDaddy SiteSealWebTrust
Go to Top